aldosterone has been researched along with Glycosuria in 12 studies
Glycosuria: The appearance of an abnormally large amount of GLUCOSE in the urine, such as more than 500 mg/day in adults. It can be due to HYPERGLYCEMIA or genetic defects in renal reabsorption (RENAL GLYCOSURIA).
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 10 (83.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (8.33) | 29.6817 |
2010's | 1 (8.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Amin, NB | 1 |
Wang, X | 1 |
Mitchell, JR | 1 |
Lee, DS | 1 |
Nucci, G | 1 |
Rusnak, JM | 1 |
Ackermann, TF | 1 |
Boini, KM | 1 |
Völkl, H | 1 |
Bhandaru, M | 1 |
Bareiss, PM | 1 |
Just, L | 1 |
Vallon, V | 1 |
Amann, K | 1 |
Kuhl, D | 1 |
Feng, Y | 1 |
Hammes, HP | 1 |
Lang, F | 1 |
Gilli, P | 1 |
De Paoli Vitali, E | 1 |
Tataranni, G | 1 |
Farinelli, A | 1 |
Kleinberger, G | 1 |
Suzuki, H | 1 |
Nakagawa, K | 1 |
Nakayama, H | 1 |
Kunita, H | 1 |
Hata, S | 1 |
Hori, S | 2 |
Masumura, S | 2 |
Ono, K | 2 |
Sato, Y | 1 |
Liddle, GW | 1 |
Lindheimer, MD | 1 |
Katz, AI | 1 |
Sims, EA | 1 |
Schultis, K | 1 |
Geser, CA | 1 |
Wagner, E | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of Once Daily PF-04971729 And Hydrochlorothiazide In Patients With Type 2 Diabetes Mellitus With Inadequa[NCT01096667] | Phase 2 | 194 participants (Actual) | Interventional | 2010-05-17 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Baseline 24-hour average SBP was assessed using 24-hour ambulatory blood pressure monitoring (ABPM). (NCT01096667)
Timeframe: 24 hours
Intervention | mmHg (Mean) |
---|---|
Placebo | 136.11 |
Ertugliflozin 1 mg | 133.13 |
Ertugliflozin 5 mg | 135.08 |
Ertugliflozin 25 mg | 135.59 |
HCTZ 12.5mg | 139.55 |
Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as >20 hours and <28 hours). (NCT01096667)
Timeframe: 24 hours
Intervention | grams/day (Mean) |
---|---|
Placebo | 13.35 |
Ertugliflozin 1 mg | 9.97 |
Ertugliflozin 5 mg | 8.04 |
Ertugliflozin 25 mg | 17.56 |
HCTZ 12.5mg | 6.96 |
For FPG, blood was drawn after an overnight fast of at least 8 hours (except water). (NCT01096667)
Timeframe: Baseline
Intervention | mg/dL (Mean) |
---|---|
Placebo | 169.47 |
Ertugliflozin 1 mg | 158.38 |
Ertugliflozin 5 mg | 158.29 |
Ertugliflozin 25 mg | 172.03 |
HCTZ 12.5mg | 156.87 |
Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough DBP is calculated as the mean of triplicate (3) trough DBP measures. (NCT01096667)
Timeframe: Baseline
Intervention | mmHg (Mean) |
---|---|
Placebo | 84.89 |
Ertugliflozin 1 mg | 83.08 |
Ertugliflozin 5 mg | 83.79 |
Ertugliflozin 25 mg | 83.89 |
HCTZ 12.5mg | 84.72 |
Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. Baseline trough heart rate is calculated as the mean of triplicate (3) trough heart rate measures. (NCT01096667)
Timeframe: Baseline
Intervention | beats per minute (Mean) |
---|---|
Placebo | 77.07 |
Ertugliflozin 1 mg | 78.73 |
Ertugliflozin 5 mg | 77.30 |
Ertugliflozin 25 mg | 75.63 |
HCTZ 12.5mg | 77.97 |
Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. Baseline trough SBP is calculated as the mean of triplicate (3) trough SBP measures. (NCT01096667)
Timeframe: Baseline
Intervention | mmHg (Mean) |
---|---|
Placebo | 135.17 |
Ertugliflozin 1 mg | 134.23 |
Ertugliflozin 5 mg | 137.31 |
Ertugliflozin 25 mg | 135.25 |
HCTZ 12.5mg | 138.07 |
For FPG, blood was drawn after an overnight fast of at least 8 hours (except water). (NCT01096667)
Timeframe: Baseline and Week 2
Intervention | mg/dL (Least Squares Mean) |
---|---|
Placebo | -5.44 |
Ertugliflozin 1 mg | -10.98 |
Ertugliflozin 5 mg | -22.45 |
Ertugliflozin 25 mg | -32.03 |
HCTZ 12.5mg | 3.21 |
For FPG, blood was drawn after an overnight fast of at least 8 hours (except water). (NCT01096667)
Timeframe: Baseline and Week 4
Intervention | mg/dL (Least Squares Mean) |
---|---|
Placebo | 4.39 |
Ertugliflozin 1 mg | -13.70 |
Ertugliflozin 5 mg | -30.41 |
Ertugliflozin 25 mg | -31.03 |
HCTZ 12.5mg | 3.79 |
Trough DBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments. (NCT01096667)
Timeframe: Baseline and Week 4
Intervention | mmHg (Least Squares Mean) |
---|---|
Placebo | 0.30 |
Ertugliflozin 1 mg | -0.90 |
Ertugliflozin 5 mg | -0.75 |
Ertugliflozin 25 mg | -2.71 |
HCTZ 12.5mg | -2.54 |
Trough heart rate was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the heart rate measure was obtained. Three measurements of heart rate were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments. (NCT01096667)
Timeframe: Baseline and Week 4
Intervention | beats per minute (Least Squares Mean) |
---|---|
Placebo | 2.34 |
Ertugliflozin 1 mg | -1.86 |
Ertugliflozin 5 mg | 1.22 |
Ertugliflozin 25 mg | -1.51 |
HCTZ 12.5mg | -0.99 |
Trough SBP was measured using an automated blood pressure device with the participant in a seated position for at least 5 minutes before and while the blood pressure measure is obtained. Three measurements of blood pressure were taken at least 2-minutes apart. The change from baseline at Week 4 is the difference between the baseline and Week 4 assessments. (NCT01096667)
Timeframe: Baseline and Week 4
Intervention | mmHg (Least Squares Mean) |
---|---|
Placebo | 1.24 |
Ertugliflozin 1 mg | -2.77 |
Ertugliflozin 5 mg | -5.92 |
Ertugliflozin 25 mg | -4.96 |
HCTZ 12.5mg | -3.13 |
Change from baseline on 24-hour average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. (NCT01096667)
Timeframe: Baseline and Week 4
Intervention | mmHg (Least Squares Mean) |
---|---|
Placebo | 0.77 |
Ertugliflozin 1 mg | -1.89 |
Ertugliflozin 5 mg | -2.34 |
Ertugliflozin 25 mg | -1.50 |
HCTZ 12.5mg | -1.42 |
Change from baseline in 24-hour average heart rate at Week 4 using 24 hour ABPM. (NCT01096667)
Timeframe: Baseline and Week 4
Intervention | Beats per minute (Least Squares Mean) |
---|---|
Placebo | 1.00 |
Ertugliflozin 1 mg | -1.22 |
Ertugliflozin 5 mg | 1.07 |
Ertugliflozin 25 mg | -1.39 |
HCTZ 12.5mg | -0.56 |
Change from baseline on 24-hour average SBP at Week 4 assessed using 24-hour ABPM. In the case of missing data, last observation carried forward (LOCF). (NCT01096667)
Timeframe: Baseline and Week 4
Intervention | mmHg (Least Squares Mean) |
---|---|
Placebo | 0.26 |
Ertugliflozin 1 mg | -2.71 |
Ertugliflozin 5 mg | -3.73 |
Ertugliflozin 25 mg | -3.42 |
HCTZ 12.5mg | -2.95 |
Urinary glucose excetion was corrected for a duration of 24 hours (with appropriate duration of collection defined as >20 hours and <28 hours). In the case of missing data, LOCF. (NCT01096667)
Timeframe: Baseline and Week 4
Intervention | grams/day (Least Squares Mean) |
---|---|
Placebo | 4.15 |
Ertugliflozin 1 mg | 46.33 |
Ertugliflozin 5 mg | 64.54 |
Ertugliflozin 25 mg | 74.49 |
HCTZ 12.5mg | -0.48 |
Change from baseline on daytime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
Intervention | mmHg (Least Squares Mean) |
---|---|
Placebo | 0.87 |
Ertugliflozin 1 mg | -2.12 |
Ertugliflozin 5 mg | -1.88 |
Ertugliflozin 25 mg | -1.77 |
HCTZ 12.5mg | -1.69 |
Change from baseline in daytime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
Intervention | Beats per minute (Least Squares Mean) |
---|---|
Placebo | 1.58 |
Ertugliflozin 1 mg | -1.80 |
Ertugliflozin 5 mg | 1.10 |
Ertugliflozin 25 mg | -1.07 |
HCTZ 12.5mg | -0.06 |
Change from baseline on daytime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Daytime was defined as 0600 to 2159 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
Intervention | mmHg (Least Squares Mean) |
---|---|
Placebo | 0.82 |
Ertugliflozin 1 mg | -2.88 |
Ertugliflozin 5 mg | -3.61 |
Ertugliflozin 25 mg | -4.17 |
HCTZ 12.5mg | -3.10 |
Change from baseline on nighttime average DBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
Intervention | mmHg (Least Squares Mean) |
---|---|
Placebo | 1.02 |
Ertugliflozin 1 mg | -1.48 |
Ertugliflozin 5 mg | -2.52 |
Ertugliflozin 25 mg | -0.84 |
HCTZ 12.5mg | -0.55 |
Change from baseline in 24-hour nighttime average heart rate at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
Intervention | Beats per minute (Least Squares Mean) |
---|---|
Placebo | -0.18 |
Ertugliflozin 1 mg | -0.15 |
Ertugliflozin 5 mg | 1.43 |
Ertugliflozin 25 mg | -1.99 |
HCTZ 12.5mg | -1.24 |
Change from baseline on nighttime average SBP at Week 4 using 24 hour ABPM. In the case of missing data, LOCF. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: Baseline and Week 4
Intervention | mmHg (Least Squares Mean) |
---|---|
Placebo | -0.29 |
Ertugliflozin 1 mg | -2.48 |
Ertugliflozin 5 mg | -3.47 |
Ertugliflozin 25 mg | -2.31 |
HCTZ 12.5mg | -2.30 |
An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug. Discontinuation of study drug due to an AE includes temporary and permanent discontinuation of study drug due to an AE. (NCT01096667)
Timeframe: Up to 28 days (treatment period)
Intervention | Participants (Number) |
---|---|
Placebo | 0 |
Ertugliflozin 1 mg | 0 |
Ertugliflozin 5 mg | 0 |
Ertugliflozin 25 mg | 1 |
HCTZ 12.5mg | 0 |
An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The table below includes all data collected since first dose of study drug. (NCT01096667)
Timeframe: Up to 63 days (including run-in, treatment period, and follow-up)
Intervention | Participants (Number) |
---|---|
Placebo | 9 |
Ertugliflozin 1 mg | 8 |
Ertugliflozin 5 mg | 15 |
Ertugliflozin 25 mg | 12 |
HCTZ 12.5mg | 10 |
Baseline 24-hour average DBP was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: up to 24 hours
Intervention | mmHg (Mean) | ||
---|---|---|---|
24-hr | Daytime | Nighttime | |
Ertugliflozin 1 mg | 78.67 | 81.77 | 72.05 |
Ertugliflozin 25 mg | 80.36 | 83.59 | 73.28 |
Ertugliflozin 5 mg | 80.18 | 83.47 | 73.05 |
HCTZ 12.5mg | 82.66 | 85.87 | 75.76 |
Placebo | 81.89 | 85.32 | 74.24 |
Baseline 24-hour average heart rate was assessed using 24-hour ABPM. Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: up to 24 hours
Intervention | beats per minute (Mean) | ||
---|---|---|---|
24-hr | Daytime | Nighttime | |
Ertugliflozin 1 mg | 80.74 | 83.74 | 74.44 |
Ertugliflozin 25 mg | 79.41 | 82.18 | 73.49 |
Ertugliflozin 5 mg | 79.68 | 82.71 | 73.16 |
HCTZ 12.5mg | 79.08 | 81.95 | 73.03 |
Placebo | 81.11 | 84.43 | 74.05 |
Daytime was defined as 0600 to 2159 hours, inclusive, local time. Nighttime was defined as 2200 to 0559 hours, inclusive, local time. (NCT01096667)
Timeframe: Daytime: 16 hours; Nighttime: 8 hours
Intervention | mmHg (Mean) | |
---|---|---|
Daytime | Nighttime | |
Ertugliflozin 1 mg | 136.85 | 125.15 |
Ertugliflozin 25 mg | 139.56 | 127.13 |
Ertugliflozin 5 mg | 138.89 | 126.37 |
HCTZ 12.5mg | 143.32 | 131.68 |
Placebo | 139.95 | 127.54 |
3 reviews available for aldosterone and Glycosuria
Article | Year |
---|---|
[Influence of insulinfree rehydration on diabetic derangements (author's transl)].
Topics: Acidosis; Adolescent; Adult; Aged; Aldosterone; Blood Glucose; C-Peptide; Diabetes Mellitus; Electro | 1980 |
[The effect of drugs on the endocrine function tests (author's transl)].
Topics: Adrenocorticotropic Hormone; Aldosterone; Antithyroid Agents; Biogenic Amines; Blood Glucose; Drug I | 1974 |
Renal function in normal pregnancy.
Topics: Aldosterone; Blood Urea Nitrogen; Circadian Rhythm; Estradiol; Female; Glomerular Filtration Rate; G | 1968 |
1 trial available for aldosterone and Glycosuria
Article | Year |
---|---|
Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension.
Topics: Aldosterone; Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambu | 2015 |
8 other studies available for aldosterone and Glycosuria
Article | Year |
---|---|
SGK1-sensitive renal tubular glucose reabsorption in diabetes.
Topics: Absorption; Age Factors; Aldosterone; Animals; Biological Transport; Blood Glucose; Body Weight; Cre | 2009 |
ALDOSTERONE and steroid glycosuria in the cat.
Topics: Adrenal Cortex Hormones; Aldosterone; Animals; Cats; Fludrocortisone; Glycosuria; Humans | 1958 |
Exercise-induced urinary abnormalities in long-distance runners.
Topics: Acetylglucosaminidase; Adolescent; Adult; Aldosterone; Electrolytes; Female; gamma-Glutamyltransfera | 1984 |
Effect of aldosterone on angiotensin-induced glycosuria.
Topics: Aldosterone; Angiotensin II; Animals; Glycosuria; Hyperglycemia; Injections, Intravenous; Rabbits; R | 1969 |
Mechanism of angiotensin-induce glycosuria.
Topics: Aldosterone; Angiotensin II; Animals; Blood Glucose; Epinephrine; Glycosuria; Hyperglycemia; Injecti | 1969 |
Proceedings: Blueprints for the solution of three endocrinological enigmas. The Sir Henry Dale Lecture for 1973.
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Adrenocorticotropic Hormone; Aldosterone; Blood Glucose; Ca | 1973 |
Renal function in pregnancy.
Topics: Aldosterone; Angiotensin II; Catecholamines; Estrogens; Female; Glomerular Filtration Rate; Glycosur | 1972 |
The postoperative carbohydrate, nitrogen, fat and electrolyte metabolism: aldosterone-blocking agent effect.
Topics: Adolescent; Aldosterone; Blood Glucose; Fatty Acids; Glucose; Glycosuria; Humans; Ketone Bodies; Mal | 1970 |